Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein J, Cheville JC, Comperat E, Da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez J, Maclean F, Magi-Galluzzi C, Mckenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Hes O (2021)

Publication Type: Journal article

Publication year: 2021

Journal

DOI: 10.1038/s41379-021-00737-6

Abstract

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in renal neoplasia, particularly focusing on the newly accumulated evidence post-2016 World Health Organization (WHO) classification. In the era of evolving histo-molecular classification of renal neoplasia, morphology is still key. However, entities (or groups of entities) are increasingly characterized by specific molecular features, often associated either with recognizable, specific morphologies or constellations of morphologies and corresponding immunohistochemical profiles. The correct diagnosis has clinical implications leading to better prognosis, potential clinical management with targeted therapies, may identify hereditary or syndromic associations, which may necessitate appropriate genetic testing. We hope that this undertaking will further facilitate the identification of these entities in practice. We also hope that this update will bring more clarity regarding the evolving classification of renal neoplasia and will further reduce the category of "unclassifiable renal carcinomas/tumors". We propose three categories of novel entities: (1) "Novel entity", validated by multiple independent studies; (2) "Emerging entity", good compelling data available from at least two or more independent studies, but additional validation is needed; and (3) "Provisional entity", limited data available from one or two studies, with more work required to validate them. For some entities initially described using different names, we propose new terminologies, to facilitate their recognition and to avoid further diagnostic dilemmas. Following these criteria, we propose as novel entities: eosinophilic solid and cystic renal cell carcinoma (ESC RCC), renal cell carcinoma with fibromyomatous stroma (RCC FMS) (formerly RCC with leiomyomatous or smooth muscle stroma), and anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC). Emerging entities include: eosinophilic vacuolated tumor (EVT) and thyroid-like follicular renal cell carcinoma (TLFRCC). Finally, as provisional entities, we propose low-grade oncocytic tumor (LOT), atrophic kidney-like lesion (AKLL), and biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC).

Authors with CRIS profile

Involved external institutions

University of Calgary Canada (CA) Cleveland Clinic United States (USA) (US) University of Sydney (USYD) Australia (AU) Yale University United States (USA) (US) University of British Columbia Canada (CA) The University of Tennessee Health Science Center United States (USA) (US) Johns Hopkins Hospital United States (USA) (US) Memorial Sloan Kettering Cancer Center United States (USA) (US) Indiana University United States (USA) (US) Mayo Clinic United States (USA) (US) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne France (FR) Hospitais Rede D'Or São Luiz Brazil (BR) Vanderbilt University United States (USA) (US) Peking University (PKU) / 北京大学 China (CN) Brigham and Women's Hospital (BWH) United States (USA) (US) University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US) Wakayama Medical University Japan (JP) Hospital Universitario de Cruces Spain (ES) Macquarie University Australia (AU) University of Alabama at Birmingham (UAB) United States (USA) (US) University of Michigan United States (USA) (US) Tata Memorial Hospital India (IN) University of Texas MD Anderson Cancer Center United States (USA) (US) Nanjing University China (CN) University of Toronto Canada (CA) Virginia Commonwealth University (VCU) United States (USA) (US) University of Washington United States (USA) (US) Georges Pompidou European Hospital / Hôpital Européen Georges-Pompidou (HEGP) France (FR) University of North Carolina at Chapel Hill United States (USA) (US) Tufts University United States (USA) (US) Univerzita Karlova v Praze / Charles University in Prague Czech Republic (CZ)

How to cite

APA:

Trpkov, K., Williamson, S.R., Gill, A.J., Adeniran, A.J., Agaimy, A., Alaghehbandan, R.,... Hes, O. (2021). Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology. https://doi.org/10.1038/s41379-021-00737-6

MLA:

Trpkov, Kiril, et al. "Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia." Modern Pathology (2021).

BibTeX: Download